Curasight's Board of Directors
All of the Board members and persons discharging managerial responsibilities can be reached via the Company’s address, Ole Maaløes Vej 3, 2200 Copenhagen, Denmark.
Kirsten Drejer
Chairperson of the Board 2024- (member 2021-)
Danish, Born 1956, MSc, PhD
- Board member: Zealand Pharma, Bioneer, Malin Ltd, Resother Pharma and other biotech companies (2017-)
- CEO and co-founder, Symphogen A/S (2000-2016)
- Corporate Facilitator, Novo Nordisk A/S (1997-2000)
- Director of Diabetes Discovery, Novo Nordisk A/S (1992-1996)
- Head of Diabetes Pharmacology, Novo Nordisk A/S (1991-1992)
- PhD in pharmacology – The Danish University of Pharmaceutical Science, Copenhagen University.
Ulrich Krasilnikoff
Member of the Board, CEO & CFO 2016-
Danish, Born 1967, MBA, Dipl. Ing., CPA
- CEO & CFO Curasight A/S (2016-)
- EVP Biofac Group (pharma; 2015-2016)
- Ass. Partner Capidea Capital Fund (Private equity; 2012-2014)
- Partner/EVP Mezzanin Capital A/S (Private equity; 2004-2012)
- EVP HNC Group A/S (2002-2004)
- Board member; Curasight A/S, Primodan A/S and other companies.
- Certified Public Accountant (CPA) and B.Sc in finance and accounting – Copenhagen Business School (CBS)
- MBA - University of Southern Denmark, Diploma in Engineering from DTU - Technical University of Denmark (DTU)
Andreas Kjær
Member of the Board, CSO and co-founder 2013-
Danish, Born 1963, MD, PhD, DMSc, MBA
- CSO and co-founder Curasight (2013-)
- Professor at the University of Copenhagen, Chief Physician at Rigshospitalet - the National University Hospital of Denmark (research focused on molecular imaging with PET and PET/MRI and theranostics in cancer)
- Head of Cluster for Molecular Imaging (CMI) (2004-)
- Holder of an ERC Advanced Grant, has published more than 500 peer-review articles, has received numerous prestigious scientific awards over the years.
- Member of the Danish Academy of Technica Sciences (ATV) (2015-)
- Founder FlouGuide (2018)
- Co-founder Minerva Imaging (2011).
- Founding Editor in Chief Diagnostics (2011-) and International Associate Editor Journal of Nuclear Medicine (2019-)
- MD, PhD, DMSc - University of Copenhagen, Master of Business Administration (MBA) - Copenhagen Business School (CBS)
Marcel Reichen
Member of the Board 2026-
Swiss, Born 1981, MSc, PhD, MBA
- Chief Strategy Officer, Ratio Therapeutics (2025-)
- Head S&E RLT Novartis / Advanced Accelerator Applications (AAA) (2020–2025)
- BD&L Director RLT Novartis / AAA (2022–2023)
- Strategic Project Lead Novartis / AAA (2020–2022)
- Senior Consult Bayer Business Consulting (2017–2020)
- Project manager/Group Leader iFiBiO Therapeutics (2013–2017
- MSc in Mechanical Engineering, ETH Zurich, Postdoc RA in haemotalogy University of Cambridge, PhD in Biochemical Engineering, University College London & MBA, University of St. Gallen
Dr. Colin Hayward
Member of the Board 2026-
Born 1971, MBBS, MD
- CMO, Zircomed LLC (2024–)
- Advisor and contract and fractional CMO for radiopharmaceutical & oncology companies, including Ratio Therapeutics and Z-Alpha (current)
- Advisory Board Member, Glytherix and PreTT (current)
- CMO, Telix Pharmaceuticals (2020–2024)
- CMO, Premier Research (2015–2020)
- VP Medical Affairs, Premier Research (2012–2014)
- European Medical Director, Myriad Genetics (2014–2015)
- Non-Executive Board Member, Symprove Ltd (2012–2021)
- Executive VP, Prism Ideas (2007–2012)
- International Medical Leader, Roche (2003–2007)
- Medical degree (MBBS), University of London, Fellow of the Faculty of Pharmaceutical Medicine (Board-certification equivalent) & Licensed doctor registered with the General Medical Council Registration (active)